Venture capital is vital in the early stages of developing biotechnology ecosystems, providing critical funding for scientific research and supporting founders who pursue high-risk ideas. This early investment plays a key role in moving laboratory discoveries toward clinical development by absorbing uncertainties associated with early innovation. However, experts emphasize that venture capital alone cannot sustain the growth of a biotech industry over the long term.

The transition from venture-backed startups to a stable industrial sector remains a significant challenge for many emerging biotech hubs. While venture capital thrives on risk-taking, building a sustainable biotech industry requires managing that risk through expanded infrastructure and operational capabilities. As companies mature, they must navigate complex clinical trials, regulatory approvals, global commercialization, and the establishment of manufacturing and supply chain systems—activities that go beyond the startup phase.

Industry specialists note that venture capital must evolve from merely funding early-stage companies to facilitating their progression toward institutional stability. This involves supporting strategic partnerships, encouraging mergers and acquisitions, and fostering the consolidation of complementary technologies into larger, more capable platforms. Mergers and acquisitions are particularly crucial in this phase, allowing smaller biotech firms with promising innovations to integrate into organizations better equipped for commercialization, regulatory compliance, and worldwide distribution.

In established biotech markets such as those in the United States and Europe, mergers and acquisitions are a standard part of industry growth, effectively bridging the gap between innovation and industrial maturity. For emerging ecosystems, adopting a similar approach is considered essential for scalability and long-term success. The objective of venture capital in these contexts should be to create a foundation of companies ready to evolve into industrial leaders, rather than perpetuating a cycle of perpetual startup formation.

Saudi Arabia’s biotechnology sector exemplifies this critical juncture. With ambitions to build a competitive biotech industry, the kingdom faces the imperative of transitioning from venture-stage entities to a mature industrial framework. Dr. Huda Alfardus, a biotech investment expert and advocate for expanding women's roles in business and investment, highlights the importance of this evolution in underpinning sustainable growth and economic value creation within the sector.